← Back to Search

Virus Therapy

Bacteriophage for Primary Immunodeficiency (Bacteriophage Trial)

N/A
Waitlist Available
Led By John W Sleasman, MD
Research Sponsored by University of South Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
subject/parent or guardian willing to sign consent and adhere to study schedule
known or suspected primary immune deficiency
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Bacteriophage Trial Summary

This protocol is designed to ascertain whether the bacteriophage 0X174 neoantigen is safe and effective as an antigen used in the evaluation of primary and secondary immune responses. Bacteriophage 0X174 is given intravenously 2 billion PFU/Kg of body weight; small blood specimens of 3-5 ml (about 1 teaspoon) are collected after 15 minutes, 7 days, 14 days, and 28 days. Blood is collected at intervals following the administration of the bacteriophage and the number of phage/ml is determined by the agar overlay method using suspension of E. coli C and serially diluted patient's serum. Phage-specific IgG and IgM are measured by neutralization assay. Capacity of switch from IgM to IgG is determined.

Eligible Conditions
  • Primary Immunodeficiency

Bacteriophage Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Bacteriophage Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evidence of capacity of switch from IgM to IgG.

Bacteriophage Trial Design

1Treatment groups
Experimental Treatment
Group I: BacteriophageExperimental Treatment1 Intervention
Subjects receive bacteriophage vaccinations and blood draws

Find a Location

Who is running the clinical trial?

University of South FloridaLead Sponsor
405 Previous Clinical Trials
186,419 Total Patients Enrolled
John W Sleasman, MDPrincipal InvestigatorUniversity of South Florida

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)
1995. "Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01617122.
All > Primary Immune Deficiency > Cte
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top